Background: Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment
for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barré
Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor
neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised
complications which are reviewed in this article.
Discussion and Conclusion: Most adverse events are immediate and mild such as headache, fever and
nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed
complications are rare but may be serious, including thromboembolic events and acute kidney injury,
and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg
administration and highlight practical measures to minimise complications of this therapy.
Keywords: Adverse event, immunoglobulin, inflammatory neuropathy, IVIg, safety, GBS, CIDP, MMN.
Rights & PermissionsPrintExport